Hims & Hers Health, Inc (NYSE: HIMS) will release its second-quarter earnings report after the closing bell on Monday, Aug 10, with analysts projecting significant revenue growth despite an expected net loss. The San Francisco, California-based company faces a consensus estimate for quarterly revenue of $730.12 million, a substantial increase from the $544.83 million reported in the year-ago period. However, profitability remains under pressure, as analysts expect a quarterly loss of 5 cents per share, versus earnings of 17 cents per share during the same period last year.

The divergence between revenue expansion and earnings contraction highlights the operational challenges facing the direct-to-consumer healthcare provider. While top-line growth suggests strong demand for its digital health services, the shift from profit to loss indicates rising costs or margin compression. This dynamic will be a key focus for investors during the upcoming earnings call, particularly regarding the sustainability of current growth trajectories.

Recent regulatory developments may also influence investor sentiment. On July 23, an Food and Drug Administration advisory panel voted to place the BPC-157 peptide on an allowed pharmacy compounding list. This decision could impact the company's product offerings and compliance requirements, adding another layer of complexity to its operational outlook.

Market reaction has been mixed ahead of the report. Hims & Hers Health shares gained 6.5% to close at $31.59 on Friday, reflecting some positive sentiment among traders. However, this movement occurred against the backdrop of revised analyst forecasts, suggesting that market participants are closely monitoring expert opinions for guidance on future performance.

Analyst Ratings and Price Targets

Several prominent analysts have recently adjusted their ratings and price targets for Hims & Hers Health, providing a range of perspectives on the stock's potential. The following table summarizes these recent actions:

The varying accuracy rates among these analysts, ranging from 53% to 69%, underscore the uncertainty surrounding the stock's near-term direction. Investors should consider these diverse viewpoints when evaluating their positions ahead of the earnings release.

What the Numbers Show

The most striking aspect of the current analyst consensus is the projected revenue surge of approximately 34% year-over-year, from $544.83 million to $730.12 million. This robust top-line growth contrasts sharply with the expected earnings deterioration, shifting from a profit of 17 cents per share to a loss of 5 cents per share. This pattern suggests that while Hims & Hers Health is successfully scaling its customer base or average order value, it is simultaneously facing increased operational expenses or lower margins. The ability to convert this revenue growth into sustainable profitability will be critical for long-term shareholder value.

Kessler Topaz Meltzer & Check, LLP has launched an investigation into potential securities law violations by Hims & Hers Health Inc. (NYSE: HIMS), joining a growing coalition of plaintiffs' firms scrutinizing the telehealth provider. The probe follows a July 29, 2026, lawsuit filed by the U.S. Federal Trade Commission (FTC), alongside the States of Utah and California, which accuses the company of deceptive billing and privacy practices. Shareholders who purchased securities between the relevant period and experienced losses are urged to contact attorney Jonathan Naji or other firm representatives to discuss their rights.

The FTC’s enforcement action, filed in the U.S. District Court for the Northern District of California, alleges that Hims & Hers engaged in unlawful business practices including charging consumers for prescriptions before medical consultations occurred and enrolling them in recurring subscriptions without approval. The complaint further asserts that the company deliberately made it difficult for consumers to cancel subscriptions and shared sensitive health information with third-party advertising platforms, specifically Meta Platforms Inc. and Snap Inc., despite representing that such data would remain private. The regulatory filing cites violations of the FTC Act, the Restore Online Shoppers’ Confidence Act, the Utah Consumer Sales Practices Act, and California’s False Advertising and Unfair Competition Laws.

Market Reaction and Technical Outlook

The market reacted sharply to the regulatory news, with Hims & Hers shares falling over 14% on July 29, 2026, closing at $25.00 after a $4.32 drop. Lowey Dannenberg noted an intraday decline of $3.05 per share, or approximately 10.40%, during trading on July 29, 2026. Despite the initial sell-off, the stock recovered ground in subsequent trading, rising 2.44% to close at $27.70 on Friday. This rebound placed the stock just 0.7% above its 100-day simple moving average (SMA) of $27.51. However, technical indicators remain cautious; the share price remains 14.9% below its 20-day SMA ($32.54) and 9.8% below its 50-day SMA ($30.72). The MACD indicator remains below its signal line with a negative histogram, suggesting that upside pressure may cool unless buyers can reclaim the $30.00 resistance level.

Financial Context and Company Response

The legal challenges emerge amid mixed financial performance for the telehealth provider. In the first quarter, Hims & Hers posted a loss of 40 cents per share, missing analyst estimates of 4 cents per share. Revenue totaled $608.1 million, falling below the Street consensus estimate of $616.9 million. However, the company maintains a robust outlook for the second quarter, with expected revenue between $680 million and $700 million, surpassing analyst estimates of $642.95 million. Adjusted EBITDA is projected between $35 million and $55 million.

Hims & Hers Health vehemently denied the allegations, asserting that the government’s case ignores substantial evidence provided during a nearly three-year investigation. A company representative stated that the lawsuit "disregards substantial evidence we provided the FTC during its nearly three-year investigation, ignores established state laws and industry standards in telehealth, and contorts the law to try to manufacture claims." The company characterized the enforcement action as an effort to generate headlines rather than grounded consumer protection.

What the Numbers Show

The divergence between Hims & Hers’ strong Q2 revenue guidance ($680–$700 million) and the immediate volatility highlights a market reassessment of risk. While operational metrics remain resilient, the introduction of federal litigation regarding core business practices—data monetization and billing transparency—suggests investors are pricing in significant potential liabilities beyond standard quarterly performance variances. The addition of Kessler Topaz Meltzer & Check, LLP, Lowey Dannenberg P.C., Kirby McInerney LLP, Kaplan Fox & Kilsheimer LLP, Schall, Brown & Schwartz LLP, The Law Offices of Frank R. Cruz, Holzer & Holzer, LLC, and Bragar Eagel & Squire, P.C., to the list of investigating firms signals growing confidence among plaintiffs' attorneys that the FTC's findings may support viable securities fraud claims, even as technical indicators suggest the stock is attempting to base near its 100-day SMA.